The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study

Affiliations

¹ Faculté de médecine, Université de Lille, France. Electronic address: m.panhaleux@gmail.com.
² Internal Medicine and Clinical Immunology Department, Univ. Lille, CHU Lille, Inserm, Centre de référence des maladies autoimmunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), U1286 - INFINITE - Institute for Translational Research in Inflammation, 59000, Lille, France.
³ Lille University and Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
⁴ Internal Medicine and Clinical Immunology Department, APHP, University Hospital Bicêtre, Le Kremlin Bicêtre, Paris Sud 11 University, France.

Comment

Marion Panhaleux et al. Eur J Cancer. 2022 Apr.

. 2022 Apr:165:208-209.

doi: 10.1016/j.ejca.2022.01.021. Epub 2022 Feb 27.

¹ Faculté de médecine, Université de Lille, France. Electronic address: m.panhaleux@gmail.com.
² Internal Medicine and Clinical Immunology Department, Univ. Lille, CHU Lille, Inserm, Centre de référence des maladies autoimmunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), U1286 - INFINITE - Institute for Translational Research in Inflammation, 59000, Lille, France.
³ Lille University and Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
⁴ Internal Medicine and Clinical Immunology Department, APHP, University Hospital Bicêtre, Le Kremlin Bicêtre, Paris Sud 11 University, France.

No abstract available

Conflict of interest statement

Conflict of interest statement None declared.

Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study.
Panhaleux M, Espitia O, Terrier B, Manson G, Maria A, Humbert S, Godbert B, Perrin J, Achille A, Arrondeau J, Kostine M, Fallet V, Pugnet G, Chaigne B, Champiat S, Laparra A, Danlos FX, Launay D, Penel N, Lambotte O, Michot JM, Forestier A. Panhaleux M, et al. Eur J Cancer. 2022 Jan;160:134-139. doi: 10.1016/j.ejca.2021.10.018. Epub 2021 Nov 19. Eur J Cancer. 2022. PMID: 34810048 Clinical Trial.
Letter comments on anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study.
Ikeda S, Yamaguchi Y, Baba T, Sekine A, Ogura T. Ikeda S, et al. Eur J Cancer. 2022 Apr;165:205-207. doi: 10.1016/j.ejca.2022.01.020. Epub 2022 Feb 26. Eur J Cancer. 2022. PMID: 35232628 No abstract available.